Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab
Karolinska Inst, Sci Life Lab, Drug Discovery & Dev Platform, Stockholm, Sweden.;Karolinska Inst, Div Translat Med & Chem Biol, Dept Med Biochem & Biophys, Stockholm, Sweden.;Univ KwaZulu Natal, Catalysis & Peptide Res Unit, Durban, South Africa..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry. Uppsala University, Science for Life Laboratory, SciLifeLab. Karolinska Inst, Physiol & Pharmacol, Stockholm, Sweden..
KellSa Sas, Str Campo & Zampe 12, I-13900 Biella, BI, Italy..
2017 (English)In: FUTURE SCIENCE OA, ISSN 2056-5623, Vol. 3, no 2, article id FSO176Article in journal (Other (popular science, discussion, etc.)) Published
Abstract [en]

The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish academic researchers with large-scale technologies for molecular biosciences with a focus on health and environment. SciLifeLab was created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University, and has recently expanded to other Swedish university locations. The primary goal of the SciLifeLab DDD is to support selected academic discovery and development research projects with tools and resources to discover novel lead therapeutics, either molecules or human antibodies. Intellectual property developed with the help of SciLifeLab DDD is wholly owned by the academic research group. The bulk of SciLifeLab DDD's research and service activities are funded from the Swedish state, with only consumables paid by the academic research group through individual grants.

Place, publisher, year, edition, pages
2017. Vol. 3, no 2, article id FSO176
Keywords [en]
academic drug discovery, academic medical research, antibody therapeutics, biopharma, drug development, drug discovery, pharma research, small molecules
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-331950DOI: 10.4155/fsoa-2017-0013ISI: 000405987900016PubMedID: 28670468OAI: oai:DiVA.org:uu-331950DiVA, id: diva2:1151386
Available from: 2017-10-23 Created: 2017-10-23 Last updated: 2018-01-13Bibliographically approved

Open Access in DiVA

fulltext(1279 kB)13 downloads
File information
File name FULLTEXT01.pdfFile size 1279 kBChecksum SHA-512
33d1b96c7aca5fb70efcffdac8217403eff36b4e020eea8dc0fa334476f7b0078af9732449bb11bb2356173d772f422d7c4aeff0d1a55ae21701e66519d7253e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Sandberg, Kristian
By organisation
Organic Pharmaceutical ChemistryScience for Life Laboratory, SciLifeLab
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 193 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf